目的:观察含烟酰胺的润肤剂联合清洁凝胶对成人轻度特应性皮炎(AD)临床症状的影响。
方法:2022年7月至2023年1月,复旦大学附属华山医院采用单中心纳入轻度AD成人,随机和安慰剂对照方法。他们分为三组:对照组,治疗组1(T1)仅接受含烟酰胺的润肤剂,和治疗组2(T2)接受润肤剂和含烟酰胺的清洁凝胶。所有患者每天口服10mg依巴斯汀片剂。AD严重程度(SCORAD评分),瘙痒峰数字评定量表(PP-NRS),以患者为导向的湿疹测量(POEM),皮肤病生活质量指数(DLQI)评分,经皮水分流失(TEWL),由相同的皮肤科医生在第0、7、14和28天测量角质层水含量(SCWC)。
结果:共纳入122例患者,对照组38人,42在T1组和42在T2组中。研究结束时无明显不良反应,各组临床评分和角质层屏障均较基线明显改善。SCORAD,PP-NRS,DLQI,T1组TEWL和SCWC评分(分别为12.43±3、3.3±0.9、7.1±2.33、17.1±9.12、67.2±21.46)和T2组(分别为11.17±3.26、3±1.3、6.5±2.11、16.3±9.12、69.4±24.52)较对照组(分别为15.1±3.64、4.3±2.46、22.12±52.7)、终点为43、21.2、在比较POEM分数的同时,仅T2组与对照组有差异(5.2±1.4vs.6±1.6)。随访第14天,T2组TEWL和SCWC的表皮屏障参数(分别为17.57±5.24,66.46±21.38)明显优于T1组(分别为19.96±4.45,56.45±20.48)和对照组(分别为21.89±7.03,51.56±16.58)。
结论:使用含烟酰胺的润肤剂可明显改善临床症状,生活质量,轻度AD患者的皮肤屏障功能。添加含烟酰胺的清洁凝胶也可以在某些时间点影响临床疗效。
OBJECTIVE: To observe the effect of niacinamide-containing body
emollients combined with a cleansing gel on the clinical symptoms of mild atopic dermatitis (AD) in adults.
METHODS: From July 2022 to January 2023, adults with mild AD were enrolled at Huashan Hospital Affiliated to Fudan University using single-center, randomized and placebo-controlled methods. They were divided into three groups: the control group, treatment group 1 (T1) receiving niacinamide-containing body
emollients alone, and treatment group 2 (T2) receiving
emollients plus niacinamide-containing cleansing gel. All patients were orally administered 10 mg of ebastine tablets daily. AD severity (SCORAD score), peak pruritus numeric rating scale (PP-NRS), patient-oriented measure of eczema (POEM), dermatological quality of life index (DLQI) score, transepidermal water loss (TEWL), and stratum corneum water content (SCWC) were measured by the same dermatologist at days 0, 7, 14, and 28.
RESULTS: A total of 122 patients were enrolled, including 38 in the control group, 42 in the T1 group and 42 in the T2 group. There were no obvious adverse reactions at the end of the study and the clinical scores and stratum corneum barrier of all the groups improved significantly relative to baseline. The SCORAD, PP-NRS, DLQI, TEWL and SCWC scores in T1 group (12.43 ± 3, 3.3 ± 0.9, 7.1 ± 2.33, 17.1 ± 9.12, 67.2 ± 21.46, seperately) and T2 group (11.17 ± 3.26, 3 ± 1.3, 6.5 ± 2.11, 16.3 ± 9.12, 69.4 ± 24.52, seperately) were significantly improved than the control group(15.1 ± 3.64, 4.3 ± 1.7, 9.5 ± 2.46, 21.2 ± 9.47, 52.7 ± 22.43, seperately) at the endpoint of the study, while compared the POEM scores, only T2 group showed the difference with control group (5.2 ± 1.4 vs. 6 ± 1.6). The epidermal barrier parameters of TEWL and SCWC in the T2 group (17.57 ± 5.24, 66.46 ± 21.38, seperately) were significantly better than that of the T1 (19.96 ± 4.45, 56.45 ± 20.48, seperately) and control group(21.89 ± 7.03, 51.56 ± 16.58, seperately) on the 14th day of follow-up.
CONCLUSIONS: The use of niacinamide-containing body
emollients can significantly improve the clinical symptoms, quality of life, and skin barrier function in patients with mild AD. The addition of niacinamide-containing cleansing gel can also affect the clinical efficacy at certain time points.